DTIL
Precision BioSciences Inc
Mentions (24Hr)
-100.00% Today
Reddit Posts
One Interesting Stock to Watch. $DTIL
💰💰💰Good morning! #premarket #watchlist 06/22 $XELA -Secures XBP Contract Totaling $136 Million, $REV -old news. bankruptsy, $QTNT -Preview of Financials, $USWS -ProFrac Holding Corp. To Acquire U.S. Well Services, Inc, $DTIL -$50 Million Offering of Common Stock
💰💰💰Good morning! #premarket #watchlist 06/22 $XELA -Secures XBP Contract Totaling $136 Million, $REV -old news. bankruptsy, $QTNT -Preview of Financials, $USWS -ProFrac Holding Corp. To Acquire U.S. Well Services, Inc, $DTIL -$50 Million Offering of Common Stock
💰💰💰Good morning! #premarket #watchlist 06/22 $XELA -Secures XBP Contract Totaling $136 Million, $REV -old news. bankruptsy, $QTNT -Preview of Financials, $USWS -ProFrac Holding Corp. To Acquire U.S. Well Services, Inc, $DTIL -$50 Million Offering of Common Stock
💰💰💰Good morning! #premarket #watchlist 06/22 $XELA -Secures XBP Contract Totaling $136 Million, $REV -old news. bankruptsy, $QTNT -Preview of Financials, $USWS -ProFrac Holding Corp. To Acquire U.S. Well Services, Inc, $DTIL -$50 Million Offering of Common Stock
DD on DTIL (gene editing company) I am hoping people can critique
$DTIL fraction of $NTLA and $VERV but same capabilities
Mentions
SPRO - PDUFA on 6/18th, high chance of getting approved, but restrictive labeling is a minor risk as well Stocks at decent prices right now imo: AVIR, RNAC, COYA, NBP, DTIL, SLDB
DTIL has caught my attention. Gene editing company with the best gene editing tech out there and fda approved in human trials to cure hepatitis b and muscular dystrophy. Not to mention one scientist has cured 90% of herpes in rats with gene editing. SOUN has also caught my attention at its current price. I think it’s a great buy right now. Multilingual Voice ai technology that is always releasing news and almost went in the black its most recent earnings. Nvidia is invested in SOUN
Thanks for your info, man, I got smaller positions in DTIL, HELP and ACHV now.
DTIL....It's starting to move!!!
DTIL: Interesting day... Good news came out premarket. Stock was then beaten down to 52 week low of 4.45. Rest of day inched back into green, now back over 4.00. Has momentum...could be a good late afternoon/AH!
DTIL: Making a nice move after a massive dip premarket after solid phase news came out today.
DTIL: Initial pullback after good news...moving up now with increased volume!
DTIL: Twitter all over it..volume is starting to move!
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy https://www.stocktitan.net/news/DTIL/precision-bio-sciences-receives-u-s-fda-clearance-of-investigational-sji5ia1z2gcb.html
DTIL — Precision BioSciences Current shareholder and long time too
$DTIL is what im watching right now, currently doing DD I’d recommend you do the same
Check out the filings on DTIL if you’d like. Went almost all in the other day. Not financial advice
Also DTIL, could be wrong not financial advice
DTIL, Went basically all in the other day still holding for now. Not financial advice
If we can do this then can someone who has a minute look into why buying DTIL is a regarded idea. I think it might not be a regarded enough idea
I can see DTIL having that potential. Their ARCUS nuclease can do gene excision and predictable repair, which is highly differentiated from CRISPR clones. They are already dosing HBV patients right now, and will have ongoing data readout this year. They are also advancing a DMD candidate based on their excision capability, with the ability to fix stem cell dystrophin, which I view as the root cause of DMD. They also have a mitochondrial DNA editting program, which only they can do. It should also advance into the clinic within a year. They also reported a complete reaponse, a cure, for OTC defiency from a partner program earlier this year. This is proof of durability and efficacy. Risk factor is safety, efficacy, durability and scalability of their platform. And of course they will raise money repeatedly but the runway today extends to H2’26. If they can’t durably remove HBV from the patients, they will probably fold, but that remains to be seem throughout this year.
DTIL, gene editing company. They already have 1 complete response (a cure) for OTC deficiency in OTC-HOPE program. They are also seeing substantial antigen reduction in their Hepatitis B program. Both are going through Phase 1b and will have ongoing reporting. They also just started the work to advance the DMD program into the clinic. All in all, I think this bad boy got a good shot.
DTIL - They just completed a reverse split to stay listed. I cannot see this not going to the moon in 5 years. Propitery gene editing platform that works. It is now a waiting time until the trials are done in humans so they can start selling drugs and make money
The DTIL1 immediately screamed adjusted option contract. Best to stay away from those.
Resident regard here, I have 122 DTIL1 2.5C for 6/21/24. I bought them at .05 each. If i exercise them I get 3 shares of DTL per option due to the split. That means 366 shares trading at \~$12 aka \~$4300. I can then sell the shares for a profit. Is this correct or am I missing something?
Can someone explain why DTIL has 2.5C options available expiring on 6/21/24 that cost .05? Could you not buy an option now and exercise for a $10 gain on each share? Help me I'm regarded. https://preview.redd.it/hb8x25zioqqc1.png?width=1729&format=png&auto=webp&s=9903ce969da484401f232bf194643e92278f2942
Can someone explain why DTIL has 2.5C options available expiring on 6/21/24 that cost .05? Could you not buy an option now and exercise for a $10 gain on each share? Help me I'm regarded. https://preview.redd.it/5h2prff7gqqc1.png?width=1729&format=png&auto=webp&s=b760510126a1417f00a84753264e236b87a63682
Precision biosciences (DTIL) has options for $2 calls for .05 6/21/24..... Its trading at $13... Why are there no buyers? Am i regarded?
You bought a non standard option. Because of the split, the deliverable has been adjusted. If you exercised the option you would pay $750 but instead of getting 100 shares, you would get 3 shares plus $3.94 in cash. DTIL would need to trade over $200 for that option to be worth anything. [Here is the OCC memo on the adjustment.](https://infomemo.theocc.com/infomemos?number=54176) In the future, I'd suggest steering clear of illiquid options, penny stocks (or ones that have had a recent reverse split) and biotech as a whole.
$DTIL Gene editing company. Patented editing system that can do things that CRISPR cannot so they will have a market for sure. Their edits already tested on animals and recently received CTA so they can start trial on humans. They have more cash than their mkt cap. It’s an investment of a lifetime. I’m in for the long run.
Watching DTIL today. " The upfront payment of $7.5 million will consist of cash and the purchase of 2,920,816 shares of Precision common stock by TG Therapeutics at a price of $0.77 per share, a 100% premium to the 30-day volume-weighted average price (VWAP) prior to purchase. " [https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-completes-license-deal-tg-therapeutics](https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-completes-license-deal-tg-therapeutics)
I go right for the small cap companies that are trading at a great value , like #AUVI my personal fav or #DTIL if your into bio’s maybe #MIRA way over sold . But Auvi just got multiple patents granted recently one of which is being tested by the gov in the green initiative . It’s for Using the tech in HVAC or drains , tremendous growth ahead .
Thanks for the info. If you like taking chances in bio tech take a look at DTIL. At the price it’s worth picking up a few shares.
DTIL baby, give it a year or two and it will quadruple in size easily. Also CLNE because of the new infrastructure deal worth 900 million.
I'm also 18, i just started investing. It all depends on your tolerance for risk. I have a high risk tolerance, so I have some stable stocks and some volatile stocks that are higher risk higher reward. If you have a high risk tolerance, I'd buy a lot of shares of low cost stocks. Then your rewards are "magnified" in a way. For example, I have 350 shares of DTIL which I bought at 46 cents a share, and its up to 55 cents now, garnering me a 30 dollar profit off of only a 9 cent gain. If you have a low tolerance for risk, then I'd recommend stable things like ETF's or companies like google, amazon, apple, etc. But your gains will be modest if you're only investing 200 a month. Just do your research and do what you want
From 1.19 to now has been a long journey for me. I hope $ADMA growth continues and stabilizes. This is the focal point of my bios investment, along with $CABA and $BDTX, as well as some other plays that I still expect to come on their own, such as $DTIL and $PASG.
May I introduce you to DTIL.
I am in $DTIL and $OCGN for a week or two.
DTIL is about to go off!!! You can afford atleast 1 ;)
DTIL is about to go off!!!! You can buy atleast 1.
Hey /u/marketartillery - I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: DTIL CABA. We don't allow discussion of low market cap (less than 500mm) tickers to prevent pump & dump spam and scammers.
DTIL - but it’s super risky play right now Reason • PRECISION BIOSCIENCES ANNOUNCES IN VIVO GENE EDITING COLLABORATION WITH NOVARTIS TO DEVELOP POTENTIALLY CURATIVE TREATMENT FOR DISORDERS INCLUDING SICKLE CELL DISEASE • PRECISION BIOSCIENCES INC - PRECISION TO RECEIVE $75 MILLION UPFRONT FOR A SINGLE TARGET • PRECISION BIOSCIENCES - PRECISION ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $1.4 BILLION IN MILESTONES AND TIERED ROYALTIES ON SALES OF LICENSED PRODUCTS • PRECISION BIOSCIENCES INC - EXTENDS PRECISION'S CASH RUNWAY INTO Q2 2024
DTIL 200 millions+ cash. Billions in collaboration deal with LLY NVS. Comparable stocks CRSP BEAM NTLA FATE gene editing.
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: DTIL. Message /u/zjz if they're above 500 million-ish market cap and not related to crypto/pennies/OTC.
EVFM ....XELA....TBLT (for damn sure).....and a little one I seen is DTIL. Let's get this damn money!!
Well genomics is in the same state right now. In 20 years it will blow up. CRSPR, EDIT, DTIL, MBIO etc.
No one is talking about DTIL 🤔 which will amaze everyone. Boxd, muln, Kirk, Rad and sft
I am a bot. You submitted a picture of a banned ticker, DTIL. The market cap of DTIL is **71502870** This check will fire if you included unnecessary pictures that have bad keywords/phrases. Repost with the useless pictures omitted if you did that.
There's tremendous opportunity in the sector but the future is unknown. The application of gene editing for cancer treatment is largely unproven still. You might want to hunt around on some genomics or oncology forums for better insights. I'm adding DTIL and MRNA in the sector.
If you’re gonna buy calls in this market, check out DTIL. Cheap calls and a good time to buy IMO
Should’ve bought DTIL calls to expire in September, they’re cheaper and more likely gonna get you a pretty penny
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: DTIL. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC.
If DTIL saves the banana, could be a good catalyst
Biotech is beaten down and I'm bullish on this clinical trial. So XBI and DTIL. https://clinicaltrials.gov/ct2/show/NCT04649112?term=precision+biosciences&draw=2&rank=1
DTIL - Precision Bio has gone under the radar, I feel they are undervalued currently relative to their value. I also hit it big and hold Editas, Intellia, CRSPR Therapeutics, and swung trade Carribou. I work at a university, and see these technologies in use everyday (not an expert), but can feel the enthusiasm and so I’ve bought into the hype. Just one of these gets FDA approval and it sends the sector flying; realize this is a platform technology, even if one treatment fails, there will be more bites at the apple.
I've been buying DTIL, precision bioscience. They use a different gene editing tool that the crispr cas9, something more specific, smaller, but potentially it can trigger more immune response, I think. I am not a researcher. Their approach, ARCUS, is proprietary and over my head, but it's worth putting a little bit on, since they own all patents associated with it and they have some positive preliminary data and affiliations.
DTIL Haven't seen this mentioned and it's definitely one of life's gambles, also far riskier than most other stocks mentioned so far. Be under no illusion, you could loose 80% or all your investment. **What do they do?** \- Gene editing & CAR-T, also have work ongoing with editing...bananas (yes there is a real problem) **Why?** Well they seem priced to fail, small market cap ($550m), they have trials ongoing, data readouts dropping between now and next June. Trade far lower than peers in market cap terms (NTLA, CRSP, EDIT, BEAM). Most interesting is the Eli Lily $100m investment they received. Could 10x...or fail of course.
Ill be honest ARKG is no longer genomic revolution. Its "healthcare revolution". Id rather invest 20% each in CRSP, EDIT, NTLA, DTIL, BEAM than ARKG right now
I'd also throw in CRSP, DTIL and NTLA. If methods like CRISPR work as we expect them to, genomics stocks will experience what tech stocks experienced during the last 15 years. Best case scenario is that they will have a cure for all genetics related diseases. How much is that worth? A trillion? 10 Trillion? More? What price do you put on global health? Worst case scenario is that it doesn't work and then these will be almost worthless.
DTIL is also working on a CAR-T therapy, but for lymphoma instead of solid tumors like Ziopharm. They are at a similar stage (ongoing phase 1/2) trial. They do have some good [preliminary results](https://www.globenewswire.com/news-release/2020/12/04/2139730/0/en/Precision-BioSciences-Reports-Positive-Interim-Results-from-PBCAR0191-Phase-1-2a-Trial-in-Relapsed-Refractory-R-R-Non-Hodgkin-Lymphoma-NHL-and-R-R-B-cell-Acute-Lymphoblastic-Leukem.html) out, but only from 27 patients and not peer-reviewed. They'll have to do at the very least one more trial with very good results in order to get a commercial product from an Accelerated Approval pathway. I like that they're are pursuing an off-the-shelf strategy (as opposed to modifying individual patients' T cells), but they're still years away in a crowded space.
DTIL to the MOON 🌙 🌝 Woo!
DTIL - Up there in terms of technology with CRSP and other bio technologies. Have a huge partnership with Eli Lilly. Holding for the long term
In order: DTIL, ISRG, STEM, AMZN, M.ARA (bot is erroneously triggering)
yes check latest news from DTIL - it jumped quite a bit today and i think it is legit acquisition target. Wish i can be patient and lucky enough to see it bounce back to its highs and beyond
One that hasn't rallied is DTIL, I looked around, having a science background and I work in healthcare (not an oncologist or geneticist), but their platform seems legit. They have a collaboration with Yale. I've been buying little bits here and there
What are your thoughts on DTIL. They claim to do the same as CRSP but better with their own IP
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: DTIL DTIL AAV. Message /u/zjz if they're above 1.25 billion-ish market cap and not related to crypto/pennies/OTC/SPACs.
DTIL could work out but (IMO) it’s low market cap for a reason and accurately priced. Their system is less flexible than CRISPR/cas and it’s not really clear to me that it can be successfully targeted to a wide variety of genome locations. I think it’s more limited tech and that crispr and cas proteins are going to get to the easiest to cure diseases before DTIL and meganucleases do. Plus, base editors and BEAM are huge competition for the more limited but higher precision editing niche and base editors are easier to target to new diseases than meganucleases
Because meganucleases are more limited technology that is less likely to be a game changer than CRISPR and associated proteins due to the difficulty in programming the nucleases to recognize new DNA sequences. Intellia had a major breakthrough with a successful phase 1 in vivo cas9 trial, but this doesn’t address the questions/concerns with meganucleases. I was looking into DTIL a couple months ago and the limitations I first thought of when I read about the tech + the lack of new papers/scientific interest over the last 10 years (do a google scholar search for their main gene editing protein or just “meganucleases” and compare number of results to cas proteins) has me thinking that DTIL is as low market cap as it is for a reason
No, but i have small amount of DTIL and ARKG
DTIL is worth looking into as well. They might be small cap but they have their own proprietary gene editing tech that has some advantages over CRISPR, and also work with Eli Lilly to make novel drugs/ treatments.
I’m in Edit too, sold CRISPR at around 160 and bought 2 year long options. I’m also in DTIL and MBIO for the long term too
All the money is pumping into DTIL, CLOV, GME, AMC. The hedge funds have figured out the algorithms to make those work for them and have their trolls in Wall Street pumping and swaying everything. All the fools are going to lose their shirts. I just bought 300 more shares and am very comfortable with what I've just done.
what other stock (other than BEAM) with prime and base editing? Crispr cas9: EDIT, CRSP, NTLA ZFN : SGMO Arcus : DTIL Prime : BEAM Talen : BLUE This is like asking "what's your favorite smartphone maker stock that use iOS?"
Precision Biosciences, Inc. (DTIL) A small cancer research company in NC. One of the therapies they’ve been working on is in a Phase 1/2a trial. It’s been used on only 13 patients with CD19+ Non-Hodgkin lymphoma, but 77% of them have been responding to the therapy. It’s been gaining over the last couple weeks and I hope it explodes soon!
Doing the same. I have a perfectionist personality and I am not good at "doing poorly," but I am NOT selling stocks that will almost all - if not every single one of them - recover and go to new highs. I have Apple, LAM, Tesla, Microsoft, Pins, Etsy, ABNB, LEV, BABA, Disney, DTIL, AMRS, and VTI. I started contributing to Roth this year, and even my index funds in there are red. I'm just trying to figure out what to buy more of without running out of cash.
Would that be Arena? What do you think about others such as EDIT, NVTA, DTIL, BNGO, NTLA, ILMN, BMY and PACB?
EDIT is about to explode this week and take the whole genome editing companies with it EDIT CRSP NTLA BEAM DTIL https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-present-preclinical-data-demonstrating
Thanks DTIL for breaking 10 again. Now let's rip to 15!
Good morning to everyone except the SGMO and DTIL people
There are so many, personally I have EDIT, CRSPR, DTIL, VRTX, NVTA, OLMA. Plan to add PACB. Might add NTLA, not sure about Illumina as they have such a high share price already
My punts are DTIL, EDIT, CRSP, NVTA, OLMA and a firm who I’m not allowed to mention that is involved in LIDAR
I would just ignore him and do your own thing. If you want to follow someone else’s advice then eToro is perfect for that with their copy trader facility. I’m in the U.K. and I do like eToro as it’s simple to use. I mostly use interactive broker though as they give access to the US markets in after hours/pre market trading. Some of my favourites are genome stocks which have all fallen again last week, DTIL massively oversold, EDIT rumoured to be releasing a positive update possibly this week, CRSP and NVTA are both cheap and away from genome stocks MVIS also sounds on the cusp of good news
GME, MVIS, APHA and also DTIL a bargain that will bounce back soon enough
> I’ve bought some DTIL this week as really feels like the stock has been oversold too much. I’ve not been investing a very long time though, wondering if anyone has seen a sell off like this before? I don't know the company but biotech and life science names - especially smaller, more speculative names - have been impacted lately and in some cases obliterated. Collaborations/etc often don't really matter when you have rotations like you've had out of growth in the last month or two. Again, I don't know the company but if you have a long term view you buy some, if it goes down another 5% you buy a little more, etc.
DTIL- surely oversold and worth buying not selling? Precision Biosciences (DTIL) has dropped in price as a result of the CEO announcing he plans to leave at some point when they have found a suitable replacement, and following a smooth handover period. It is currently $8.86 and it feels massively oversold to me and surely it is prime to bounce back before long? They announced the collaboration in January with the upfront payment of $100 million and the amounts they are scheduled to receive in the future. It just doesn’t feel like it should be this low?? I’ve just added some and hoping my gut is correct!
DTIL for me. I wonder if anyone here holds it? I don't know why they're looking for a new CEO.
You sound like you know what you’re talking about. So if you haven’t heard of these tickers, you should check out CVM, NKTR, SCYX, AGEN, DTIL
Ive got $400k cash and started to buy some today. Got some CRM and DTIL at close. Hopefully my fellow cash gang are following suit.
Deciding on dumb shit like DTIL leaps and STPK fds, but probably gonna open a frozen semen brokerage for stallions.
This company shows up like every year. The vaccine doesn't "cure" brain cancer, it adds on to standards (radiation/gamma knife or surgical resection) to lengthen survival. Even then the terminal numbers are dismal, with a few extra years of survival vs 14 months. So it's not accurate to say "cure." If I had GBM I'd obviously want extra years vs months, so I don't want to downplay the possible importance. I didn't read the .gov trial submission to see what they're really doing, fwiw, so I don't know what (sub)population they are targeting. It's worth a few hundred bucks but not a yolo imo. I'm in the medical field and hate most all biopharms except AXSM, DTIL and SGMO (for the meme). For every 200% rando, you have 100 penny duds.
Idk it's been a while since I read up on it but AGTC uses viral vectors for genetic modification which historically isn't very good, I think DTIL has the more promising technology but it's financials don't look great. Staying out of both personally but AGTC might be able to do a few swings $5-$9 range imo